8-K - Biogen Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Biogen Inc. announced a definitive agreement to acquire Apellis Pharmaceuticals for $41 per share in cash plus a CVR, adding SYFOVRE and EMPAVELI to enhance its immunology and nephrology growth portfolio.

Key Takeaways

1Biogen to acquire all Apellis shares via tender offer at $41 cash per share (~$5.6B equity value) plus non-transferable CVR worth up to $4/share tied to SYFOVRE net sales milestones.

2Apellis' SYFOVRE (GA) generated revenue with mid-high teens growth expected through 2028; EMPAVELI approved in C3G/IC-MPGN and PNH, accelerating Biogen's nephrology entry.

3Transaction expected accretive to non-GAAP EPS starting 2027, boosting Biogen's EPS CAGR through decade-end; financed with cash and debt, full deleveraging by 2027.

4Offer conditions include Minimum Condition (>50% tendered), HSR clearance; expected close Q2 2026.

5Apellis Board unanimously approved; key insiders (~14% shares) signed tender/support agreements.

6Brings U.S. nephrology infrastructure to support Biogen's felzartamab Phase 3 readouts starting H1 2027.

Current Report Details

Event Type

Material Agreement

Other Event

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. Agreement and Plan of Merger On March 31, 2026, Biogen Inc., a Delaware corporation (“Biogen”), entered into an Agre

Material Agreement

$41.00$4.00

8.01

Other Events. Press Release On March 31, 2026, Biogen and Apellis issued a joint press release announcing the entry into the Merger Agreement. A copy of the pre

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No.: 2.1* | Description: Agreement and Plan of Merger, dated as of March 31, 2026, by and among Apellis

Exhibits Only

Source Document

Exhibits (5)

2.1

EX-2.1

8-K

99.1

EX-99.1

99.2

EX-99.2

99.3

EX-99.3